Trial reportCancer discovery2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with
Erratum issuedAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph
Trial report in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 121 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.Journal of cancer research and clinical oncology · 2022Pooled it
- Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.Nature communications · 2025Trial
- First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.International journal of clinical oncology · 2024Trial
- SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study.Signal transduction and targeted therapy · 2024Trial
- Trial
- Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.Clinical pharmacology and therapeutics · 2022Trial
- Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer.CPT: pharmacometrics & systems pharmacology · 2022Trial
- Trial
- FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.Medicines (Basel, Switzerland) · 2026Review
- Therapeutic Advances in Non-Small Cell Lung Cancer HarboringInternational journal of molecular sciences · 2026Review
- AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers.NPJ precision oncology · 2026Article
- Article
- Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations.Investigational new drugs · 2025Review
- AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions.Cell reports. Medicine · 2025Article
- Current paradigm of EGFRMed (New York, N.Y.) · 2025Review
- STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Review
- Osimertinib for uncommon EGFR mutations: herding UNICORNs in a field of horses.Translational cancer research · 2025Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
22 authors.
Gregory J RielyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York. rielyg@MSKCC.ORG.
Joel W NealDepartment of Medicine, Division of Oncology, Stanford University, Stanford, California.ORCID 0000-0003-3119-9334
D Ross CamidgeDepartment of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado.
Alexander I SpiraDepartment of Thoracic Oncology, Virginia Cancer Specialists, Fairfax, Virginia.
Zofia PiotrowskaDepartment of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Daniel B CostaDepartment of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Anne S TsaoDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0505-6639
Jyoti D PatelDepartment of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
Shirish M GadgeelDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan.
Lyudmila BazhenovaDepartment of Medicine, UC San Diego Moores Cancer Center, La Jolla, California.ORCID 0000-0001-8764-4359
Viola W ZhuDepartment of Medicine, Division of Hematology/Oncology, University of California, Irvine, Orange, California.
Howard L WestDepartment of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.
Tarek MekhailThoracic Cancer Program, AdventHealth Orlando, Orlando, Florida.
Ryan D GentzlerHematology/Oncology, University of Virginia Cancer Center, Charlottesville, Virginia.ORCID 0000-0002-8983-6677
Danny NguyenDepartment of Hematology and Oncology, Pacific Shores Medical Group, Long Beach, California.ORCID 0000-0002-2479-2271
Sylvie VincentMillennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.ORCID 0000-0002-7247-2467
Steven ZhangMillennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Jianchang LinStatistical and Quantitative Sciences, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Veronica BunnMillennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Shu JinMillennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.ORCID 0000-0003-2977-7625
Shuanglian LiMillennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Pasi A JänneLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MUnmet needs for specific subsets of EGFR mutated lung cancerR37CA218707 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI COSTA, DANIEL BOTELHO · 2018 to 2024
$2.8MNCI NIH HHS P30 CA008748NCI NIH HHS R37 CA218707
Abstract
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting
Indexed as
ExonsAdultAgedAged, 80 and overAniline CompoundsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleHumansIndolesLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedMutagenesis, InsertionalAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsIndolesmobocertinibPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.